Friday - March 14, 2025
UT-MD Anderson Cancer Center: Combination of Dual-Targeted Therapies and Chemotherapy Shows High Response Rates in BRAF-Mutated Metastatic Colorectal Cancer
January 27, 2025
HOUSTON, Texas, Jan. 27 (TNSres) -- The University of Texas MD Anderson Cancer Center issued the following news release:

* * *

Phase III trial results supported recent FDA approval for patients with BRAF V600E mutations

ABSTRACT: 16 (https://meetings.asco.org/abstracts-presentations/241160)

* * *

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted t . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation
Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products